Skip to content
‹ Back to IndustriesHealthcare

Siemens Healthineers starts carving out its 16-billion-test diagnostics business as Olyrian Diagnostics

Siemens Healthineers has begun carving out its diagnostics business, which the company says makes more than 16 billion tests a year. The unit will take the name Olyrian Diagnostics, and the company expects the internal separation to be finished by mid-2028. Reuters reported that the rebrand comes ahead of a future divestment, though no buyer, listing or other structure has been named. As of the announcement, the company says contracts and service levels have not changed. For labs, the change is most likely to show up in agreements that run past mid-2028.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · Siemens HealthineersOlyrian DiagnosticsHealthineersIn Vitro Diagnostics
Share
Siemens Healthineers starts carving out its 16-billion-test diagnostics business as Olyrian Diagnostics

Key takeaways

01

A lab contract that runs past mid-2028 could finish its term with Olyrian Diagnostics as the supplier.

02

The diagnostics unit is about one in five Siemens Healthineers employees, so the separation means building standalone functions, which is a bigger job than putting up a new logo.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

On November 5, Siemens Healthineers announced that the carve-out of its diagnostics business was under way. The unit will be rebranded as Olyrian Diagnostics. According to Reuters, it runs more than 16 billion tests each year, and the company expects to finish the separation by mid-2028.

Siemens Healthineers will become Healthineers, and the two rebrands will run side by side. Reuters reporters Kira Britten and Paolo Laudani described the Olyrian rebrand as a step ahead of a future divestment of the unit.

That leaves a practical question for lab directors and the procurement leads who sign reagent and service agreements for Siemens Healthineers analyzers, automation lines and point-of-care devices: what changes, and when? For now the answer is nothing. Clinical Lab Products reported that, as of the announcement, products and services, contracts, service levels and customer points of contact all stay the same, and that the company will tell customers directly about any future changes as the carve-out moves forward.

A 140-year-old lab business gets its own name

Olyrian has a long history behind it. According to Clinical Lab Products, Siemens Healthineers put together its in vitro diagnostics unit through three acquisitions made in 2006 and 2007, and the roots of those companies go back as far as 1884. Among the milestones cited in the announcement are the first urine test strip for diabetes and the first analyzer in the industry to combine clinical chemistry and immunoassay testing in one automated, integrated system. Today the portfolio covers laboratory automation, informatics and point-of-care testing solutions, and the company says its assays address nearly every major disease area.

Olyrian will sell diagnostics for lab and point-of-care testing, a range the company says covers everything from patient draw to population health. The company says its purpose is to power human potential at the heart of care. It links that goal to two things: an exclusive focus on in vitro diagnostics, and pairing intelligent technology with the know-how of the people who produce, interpret and act on diagnostic information.

Sharon Bracken, head of diagnostics at Siemens Healthineers, presented the new name as the start of the business's next phase. In the release, she said the laboratory sits at the heart of care, and that each day the business helps care teams deliver the critical answers patients need. "Olyrian Diagnostics is how we'll define our next chapter," she said. The company says a dedicated brand will position the unit as one of the largest standalone companies focused only on diagnostics.

For a lab buyer, that "singular focus" language describes a supplier whose whole business would be the analyzers, assays and informatics the lab already runs. Today those products sit alongside imaging and therapy lines inside a broader medtech group.

What Siemens Healthineers is separating

16 billion+
Tests made each year
~17%
Share of group revenue from the diagnostics unit
~20%
Share of the group's workforce in the diagnostics unit
Mid-2028
Expected completion of the separation

Reuters; Clinical Lab Products

The workforce number tells you what kind of job this is. When one in five employees sits in the unit being separated, the company has to build standalone functions alongside the new brand. The sources don't say how many roles move or where. Still, the scale could help explain why the separation is not expected to finish until mid-2028.

A double separation, and the contracts that outlast it

The rename is one layer of a wider restructuring, and the separation runs in two directions at once. The Wall Street Journal's Adrià Calatayud reported that the parent is dropping Siemens from its name as it advances toward a spinoff from its own parent group. In 2025, Siemens laid out plans to deconsolidate Healthineers by spinning off a 30% stake to shareholders.

At the same time, Healthineers is carving out its diagnostics unit, a rebrand the Journal described as the first step toward establishing a standalone company. The Olyrian name will arrive in stages rather than on a single date. So a lab buying from Siemens Healthineers today is dealing with a company that is stepping away from its own parent while also separating out the very unit the lab buys from.

Contract timing is where this hits lab operations. A lab contract that runs past mid-2028 could finish its term with Olyrian Diagnostics as the supplier. For labs about to sign longer agreements, the timeline is worth putting on the table during negotiation, since the company has said future changes will be communicated as they happen.

During the transition, Olyrian Diagnostics stays inside Siemens Healthineers. The carve-out is the internal separation that comes first. Reuters describes it as preparation for a future divestment, and no buyer, listing or other structure has been named.

Margins, savings and stranded costs

Reuters set out the numbers behind the decision. In the fourth quarter, the diagnostics unit's adjusted EBIT margin came in at 5.4%, and its transformation program aims to deliver another 400 million euros (about $450 million) in savings. On the analyst call, CFO Jochen Schmitz said the business will keep working toward mid-teens margins over the medium term. Reuters linked recent pressure on the unit to market conditions in China after healthcare reforms there, and the company forecast slower-than-expected group growth for fiscal 2027.

Schmitz added that splitting off the unit would bring carve-out and stranded costs in the near term. Over the longer term, he said, the result would be a more focused business. Deutsche Bank described the quarterly results as "disappointing" but called the decision to separate the diagnostics business "sensible".

Put those statements side by side and the order of events is clear. Getting from a 5.4% quarterly margin to mid-teens would mean more than doubling it, and the separation adds its own costs before the focus pays off. Deutsche Bank's split verdict suggests at least one analyst house is weighing that longer-term focus more heavily than the weak quarter.

One reasonable worry is that a savings program running alongside a separation could squeeze customer support. The evidence doesn't point that way so far. The company has said in writing that service levels are unchanged, and a standalone diagnostics company would depend on its installed base of labs more than its current parent does. Even so, lab procurement leads can fairly ask how the 400 million euro program touches field service and applications support during the transition.

The ultrasound exit as a reference point

Radiology Business editor Hannah Murphy reported that on October 12 the company stopped all sales of its general imaging ultrasound systems: the Acuson Sequoia, Redwood, Juniper and Maple. It still sells procedural products, including the Acuson Origin cardiovascular platform, the P500 intracardiac echocardiography system and the Freestyle system, along with software and catheters. Cardiovascular Business described the shift as a focus on equipment used by electrophysiologists and interventional cardiologists.

Sourabh Pagaria, head of Ultrasound, explained the move this way: "Medicine is evolving, and imaging is increasingly becoming part of therapy, not just diagnosis." The company said general imaging ultrasound is a market well served by multiple established providers. It expects procedural imaging, particularly electrophysiology and structural heart work where demand for image guidance has grown, to offer more long-term growth as minimally invasive treatments gain ground in cardiovascular care.

It also said that leaving the segment reflects a narrower business focus rather than an end to support for its installed base. That idea of narrowing links the two moves. Ultrasound narrowed toward procedures. Diagnostics is becoming a company whose stated purpose rests on a singular focus on in vitro diagnostics.

For existing ultrasound customers, the company committed to maintenance, software updates, transducer availability, and meeting contractual and regulatory obligations for the life of the systems. That is the clearest recent example of how Healthineers words its promises to an installed base when its portfolio changes. The two cases differ in one important way, though. Ultrasound was an exit from selling a product line. Olyrian will keep selling the whole diagnostics portfolio under a new structure, so the ultrasound terms show the kind of language to expect, not what will happen.

For any diagnostics agreement that runs past mid-2028, use the ultrasound commitments as a checklist: ask how maintenance, software updates, parts and consumables availability, contractual obligations and named points of contact carry over to Olyrian Diagnostics.

The first real signs will be the staged arrival of the Olyrian name and whatever the company sends customers directly about contracts as the separation moves forward. As of the announcement, the company says there is no change to products, contracts, service levels or customer points of contact.

Featured companies

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Up to 0.864 in U.S. and Austrian ICUs, 0.698 in China

Up to 0.864 in U.S. and Austrian ICUs, 0.698 in China

ELDER-ICU, an ICU mortality prediction model for patients 65+, reached up to 0.864 AUROC in U.S. and Austrian cohorts but 0.698 at a site in China. The results highlight that performance can vary across settings, so hospitals buying AI built elsewhere should validate it on local patients and ensure contracts allow recalibration or retraining when needed.

  • 01A vendor's validation claim is only as good as the patients it was tested on: one ICU mortality model scored 0.804 to 0.864 AUROC in U.S. and Austrian hospitals and 0.698 in China.
  • 02Match the fix to the failure. Recalibration improved probability accuracy at every site, while only retraining on local data recovered the bigger ranking losses at the South Korean and Chinese sites (+0.066 and +0.076 AUROC).
  • 03Checking AI on local patients takes staff and contract terms: whether the license permits local recalibration or retraining, and who on the team can run it.

Nov 17, 2026

Epic's seven bets beyond the EHR, sorted by when hospitals can actually use them

Epic's seven bets beyond the EHR, sorted by when hospitals can actually use them

Epic is expanding past its EHR into ERP, IT staffing, AI, drug pricing and payer technology. Delivery runs from tools live today to a full EpicOps rollout that may not arrive until 2029. The payer platform has the clearest proof point: St. Luke's and UnitedHealthcare automated status updates on 88% of the claims they exchanged.

  • 01Epic's payer platform is the expansion bet with a measured result: 88% of claim status updates automated between St. Luke's and UnitedHealthcare, plus a 25% drop in status calls.
  • 02EpicOps, Epic's ERP suite, may not be fully available until 2029, so a health system whose ERP commitments end sooner can test individual modules alongside its current system without a full switch.
  • 03Before using any integration with Epic's ambient AI, verify in your environment that the necessary write operations are supported, as FHIR support doesn't ensure full access.

Nov 16, 2026

Avanlee Care’s $3.5M seed tests whether Medicare Advantage plans will pay to reach caregivers

Avanlee Care’s $3.5M seed tests whether Medicare Advantage plans will pay to reach caregivers

Avanlee Care raised a $3.5 million seed round led by BEA Venture Fund, bringing total funding to $6 million. The startup helps Medicare Advantage plans find and support members' family caregivers. Its bet: plans will pay to reach whoever books the visits.

  • 01Medicare Advantage plans can see overdue visits and refills; Avanlee Care’s $3.5M seed backs a per-member-per-month model to reach the family caregiver who can act on that outreach.
  • 02Caregiver support among Medicare Advantage Special Needs Plans rose from 5% of plans in 2025 to 16% in 2026, even as meals and transportation benefits declined. That gives benefit designers a reference point.

Nov 15, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512